Prostate Cancer Screening Palatka FL
Prostate cancer screening consists of diagnostic tests that can assist with early detection of prostate cancer. Screening may involve a digital rectal exam, prostate-sspecific antigen (PSA) blood test, or a transrectal ultrasound. See below to learn more and to gain access to qualified oncologists in Palatka, FL who provide prostate cancer screening.
Mark Emerson Augspurger, MD
228-377-6291
600 Zeagler Dr
Palatka, FL
Mark Emerson Augspurger, MD
228-377-6291
600 Zeagler Dr
Palatka, FL 32177
Specialties
Oncology (Cancer), Radiation Oncology
Education
Medical School: Univ Of Fl Coll Of Med, Gainesville Fl 32610
Graduation Year: 1995
Data Provided by:
Anand Mathai Kuruvilla
(386) 325-8140
600 Zeagler Dr
Palatka, FL
(386) 325-8140
600 Zeagler Dr
Palatka, FL 32177
Specialty
Radiation Oncology
Data Provided by:
Anand M Kuruvilla, MD
386-325-8140
600 Zeagler Dr
Palatka, FL
Anand M Kuruvilla, MD
386-325-8140
600 Zeagler Dr
Palatka, FL 32177
Specialties
Oncology (Cancer), Radiation Oncology
Education
Medical School: Td Med Coll, Univ Of Kerala, Aleppey, Kerala, India
Graduation Year: 1979
Hospital
Hospital: Putnam Comm Med Ctr, Palatka, Fl
Group Practice: Florida Radiation Oncology Group
Data Provided by:
Ramesh T Kumar, MD
772-468-3222
1213 Highway 20 West Unit B
Interlachen, FL
Ramesh T Kumar, MD
772-468-3222
1213 Highway 20 West Unit B
Interlachen, FL 32148
Specialties
Oncology (Cancer), Radiation Oncology
Education
Medical School: Vijayanagara Inst Med Sci, Gulbarga Univ, Bellary, Karnataka, India
Graduation Year: 1987
Hospital
Hospital: Raulerson Hosp, Okeechobee, Fl; Lawnwood Reg Med Ctr, Fort Pierce, Fl
Group Practice: Mid-Florida Cancer Ctr
Data Provided by:
Wynn Sullivan
(904) 272-3139
600 Zeagler Dr
Palatka, FL
Wynn Sullivan
(904) 272-3139
600 Zeagler Dr
Palatka, FL 32177
Associated Hospitals
Putnam Community Medical Center
Joseph Wynn Sullivan, DO
904-328-8791
600 Zeagler Dr
Palatka, FL
Joseph Wynn Sullivan, DO
904-328-8791
600 Zeagler Dr
Palatka, FL 32177
Specialties
Oncology (Cancer)
Education
Medical School: Nova Se Univ, Coll Of Osteo Med, Ft Lauderdale Fl 33328
Graduation Year: 1988
Data Provided by:
Mehdi M Moez, MD
386-328-8791
600 Zeagler Dr
Palatka, FL
Mehdi M Moez, MD
386-328-8791
600 Zeagler Dr
Palatka, FL 32177
Specialties
Oncology (Cancer)
Education
Graduation Year: 2007
Data Provided by:
Mehdi Mohammad Moezi, MD
386-328-8791
600 Zeagler Dr
Palatka, FL
Mehdi Mohammad Moezi, MD
386-328-8791
600 Zeagler Dr
Palatka, FL 32177
Specialties
Oncology (Cancer), Internal Medicine
Education
Medical School: Teheran Univ, Fac Of Med, Teheran, Iran
Graduation Year: 1990
Hospital
Hospital: Orange Park Med Ctr, Orange Park, Fl; Putnam Comm Med Ctr, Palatka, Fl; Flagler Hosp, St Augustine, Fl
Group Practice: Fl Oncology Assoc
Data Provided by:
Anand Kuruvilla
904-346-3338
600 Zeagler Dr
Palatka, FL
Anand Kuruvilla
904-346-3338
600 Zeagler Dr
Palatka, FL 32177
Specialty
Radiation Oncology
Associated Hospitals
Florida Radiation Oncology Group
Pablo Ferraro, MD
(954) 430-6868
801 N Flamingo Rd
Pembroke Pines, FL
Pablo Ferraro, MD
(954) 430-6868
801 N Flamingo Rd
Pembroke Pines, FL 33028
Business
Memorial Cancer Institute
Data Provided by:
The PSA (Prostate-Specific Antigen) test is one of two primary screening tools for prostate cancer. This simple blood test measures the level of PSA, a protein produced in the prostate, present in a man's body. Men typically have an initial PSA screening at 50, or earlier if there's a family history of prostate cancer.
Physicians measure PSA in nanograms per milliliter. An elevated PSA doesn't diagnose cancer and doesn't mean a man has prostate cancer; it just suggests further evaluation. Other medical conditions can also raise PSA levels. A PSA test and additional diagnostic tools help detect small tumors, however, experts say it does not necessarily reduce a man's chance of dying of prostate cancer.
An increase in PSA is the strongest single predictor of prostate cancer risk, and a high PSA score followed by a lower PSA score is not uncommon, even in men who do have cancer. However, PSA progression does predict poor overall survival rates in men with mestacized prostate cancer (meaning it has spread beyond the prostate). The PSA test is actually a better predictor of prostate cancer risk in African-American men with family histories compared to European- American men.
There is controversy over the value of PSA screenings. This spring, researchers released the results of a large-scale study that began in 1992 to evaluate whether or not the PSA test benefited men. In the subsequent media coverage of the results, the news varied widely depending on who was doing the reporting...
Click here to read more from Quality Health